Published in Cancer Res on August 15, 1990
Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol (2009) 1.42
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol (2010) 0.86
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol (2015) 0.84
Specificity studies of an antibody developed against a mucin-type glycoprotein. Glycoconj J (1999) 0.81
In vitro reactivity and in vivo biodistribution of the monoclonal antibody A7 using human gastric carcinoma cell lines. Br J Cancer (1994) 0.75
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry (1978) 1.68
Immune deficiency in family members of patients with Hodgkin's disease. Cancer (1990) 1.61
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia (2004) 1.60
Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol (1997) 1.57
Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med (1995) 1.51
Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol (1974) 1.49
Clonal cell surface structures related to differentiation, activation and homing in B-cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance. Eur J Haematol (1989) 1.48
Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb (1992) 1.46
Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis. J Intern Med (2006) 1.46
Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease. Br J Haematol (1996) 1.45
Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Västerbotten cohort project. Stroke (2000) 1.43
Proteinuria and renal function in relation to renal morphology. A clinicopathological study of IgA nephropathy at the time of kidney biopsy. Clin Nephrol (1992) 1.41
LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol (2001) 1.39
Inversion of chromosome 14 marks human T-cell chronic lymphocytic leukaemia. Nature (1984) 1.39
Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol (1995) 1.32
A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun (2002) 1.32
In vitro activation of human T and B lymphocytes by pokeweed mitogen. Clin Exp Immunol (1975) 1.31
Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer (1995) 1.29
A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother (1985) 1.29
In vitro studies of lymphocytes from patients with plasma cell myeloma. II. Characterization by cell surface markers. Clin Exp Immunol (1973) 1.26
In vitro studies of lymphocytes from patients with plasma cell myeloma. I. Stimulation by mitogens and cytotoxic activities. Clin Exp Immunol (1973) 1.21
Acetylcholine receptor antibody in myasthenia gravis: purification and characterization. Scand J Immunol (1978) 1.19
Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1987) 1.18
IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol (1985) 1.17
Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Cancer (1976) 1.17
Anti-idiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody, in vitro effector functions and results of therapy. Cancer Immunol Immunother (1989) 1.17
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol (1998) 1.15
Receptors for Helix pomatia A haemagglutinin on leukaemic lymphocytes from patients with chronic lymphocytic leukaemia (CLL). Clin Exp Immunol (1976) 1.14
Incorporation of 125 I-labelled fibrinogen into coronary arterial thrombi in acute myocardial infarction in man. Lancet (1973) 1.13
Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Ann Oncol (1995) 1.12
Anti-idiotypic antibodies against the receptor antibodies in myasthenia gravis. Scand J Immunol (1981) 1.10
Immunoglobulins in myasthenia gravis: effect of human lymph IgG 3 and F (ab')2 fragments on a cholinergic receptor preparation from Torpedo marmorata. Eur J Clin Invest (1977) 1.10
Interferon therapy in myelomatosis. Lancet (1979) 1.10
Lymphocyte subpopulations in chronic lymphocytic leukemia. Characterization by cell surface markers, cytotoxic activity, and mitogenic stimulation. Scand J Immunol (1974) 1.09
Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand J Immunol (2001) 1.07
IgG on human blood lymphocytes studied by immunofluorescence. Scand J Immunol (1978) 1.06
Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol (1991) 1.05
Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol (1996) 1.05
Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J (2001) 1.05
Effects of some immunosuppressive procedures on myasthenia gravis. Ann N Y Acad Sci (1976) 1.04
Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol (1990) 1.03
CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood (1997) 1.02
Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol (1997) 1.02
A monoclonal anti-idiotypic antibody against anti-receptor antibodies from myasthenic sera. Eur J Immunol (1982) 1.02
Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation (2000) 1.02
Blood T-lymphocyte functions in healthy adults in relation to age. Scand J Haematol (1982) 1.01
Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol (1995) 1.01
Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer (1976) 1.00
Amplification of the c-myc oncogene in human plasma-cell leukemia. Int J Cancer (1985) 0.99
Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia (2012) 0.99
Persisting lymphocyte deficiences during remission in Hodgkin's disease. Clin Exp Immunol (1977) 0.99
NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer (2007) 0.99
T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis. Clin Exp Immunol (1995) 0.98
Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res (1995) 0.98
In vitro production of monoclonal and polyclonal immunoglobulins by peripheral blood mononuclear cells in human plasma cell myeloma. Scand J Immunol (1982) 0.98
Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood (1999) 0.98
Immunologic profile of patients with cured Hodgkin's disease. Scand J Haematol (1977) 0.98
Idiotypic immunoglobulin structures on blood lymphocytes in human plasma cell myeloma. Immunol Rev (1977) 0.97
Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol (1996) 0.97
Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation. J Clin Microbiol (2004) 0.96
Phenotypic modulation of chronic lymphocytic leukemia cells by phorbol ester: induction of IgM secretion and changes in the expression of B cell-associated surface antigens. J Immunol (1984) 0.96
Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med (2008) 0.96
Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res (1999) 0.96
Monoclonal B-lymphocytes in peripheral blood of patients with plasma cell myeloma. Relation to activity of the disease. Scand J Haematol (1976) 0.95
The large sialoglycoprotein of human lymphocytes. I. Distribution on T and B lineage cells as revealed by a monospecific chicken antibody. Eur J Immunol (1985) 0.95
Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications. Adv Cancer Res (1984) 0.95
Kinetics of cytokine gene expression in human CD4+ and CD8+ T-lymphocyte subsets using quantitative real-time PCR. Scand J Immunol (2003) 0.94
Follow-up study of muscle function in children of mothers with myasthenia gravis during pregnancy. J Child Neurol (1992) 0.94
Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood (1995) 0.94
Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis. Eur Respir J (2006) 0.94
The protein-A plaque assay: a new system for the detection of cells secreting a given idiotype. J Immunol (1980) 0.94
Helix pomatia A hemagglutinin: selectivity of binding to lymphocyte surface glycoproteins on T cells and certain B cells. Eur J Immunol (1978) 0.94
An automated turbidimetric immunoassay for plasma proteins. Scand J Clin Lab Invest (1980) 0.94
Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci U S A (1995) 0.94
Flow cytometric DNA analysis: a prognostic tool in non-Hodgkin's lymphoma. Leuk Res (1989) 0.93
Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol (1996) 0.93
Properties and serum levels of specific populations of anti-acetylcholine receptor antibodies in myasthenia gravis. Ann N Y Acad Sci (1981) 0.93
A clinical and immunological study of a myasthenia gravis patient treated with infliximab. Acta Neurol Scand (2007) 0.93
Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol (1998) 0.92
Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother (1996) 0.92
Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma (1986) 0.92
Expression of CTLA-4 by human monocytes. Scand J Immunol (2002) 0.92
Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol (1987) 0.92
Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol (2005) 0.91
T cells in monoclonal gammopathies. Scand J Haematol (1982) 0.91
Expanded T cell populations in patients with Wegener's granulomatosis: characteristics and correlates with disease activity. J Clin Immunol (1998) 0.91
Beta 2-adrenergic receptor antibodies in myasthenia gravis. J Autoimmun (1992) 0.91
Periductal lymphocytic infiltrates in salivary glands in myasthenia gravis patients lacking Sjögren's syndrome. Clin Exp Immunol (1986) 0.91
National integration of European standards. Ann Oncol (2007) 0.90
Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-up. Cancer (1991) 0.90
Acetylcholine-receptor antibodies in cerebrospinal fluid of patients with myasthenia gravis. Lancet (1977) 0.90
Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood (1991) 0.90